Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.48 |
| ▸ | ABL1 | P00519 | 3/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 15/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.47 |
| ▸ | PRKDC | P78527 | 5/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | HCK | P08631 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29651716 | 0.91 | BTK (0.49) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL11097 | 0.91 | BTK (0.49) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL131144 | 0.90 | PIK3CD (0.54) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL29651537 | 0.90 | PIK3CD (0.54) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL11412 | 0.90 | PIK3CD (0.55) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL29651614 | 0.90 | PIK3CD (0.55) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL11231 | 0.89 | PIK3CD (0.50) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL29651706 | 0.89 | PIK3CD (0.50) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL11216 | 0.88 | PIK3CD (0.50) | SRCABL1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL29651661 | 0.88 | PIK3CD (0.50) | SRCABL1PIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-20160318890-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2016-11-03 | — | — | US | disclosed |
| US-8642607-B2 | 4H-chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2014-02-04 | — | — | US | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118257-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | SRC 314/4885ABL1 465/4885PIK3CD 70/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | SRC 110/4885ABL1 258/4885PIK3CD 103/4885 |
| US-20160318890-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | SRC 314/4885ABL1 465/4885PIK3CD 70/4885 |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | SRC 314/4885ABL1 465/4885PIK3CD 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.